Elevated nuclear TDP-43 induces constitutive exon skipping
-
Published:2024-06-09
Issue:1
Volume:19
Page:
-
ISSN:1750-1326
-
Container-title:Molecular Neurodegeneration
-
language:en
-
Short-container-title:Mol Neurodegeneration
Author:
Carmen-Orozco Rogger P., Tsao William, Ye Yingzhi, Sinha Irika R., Chang Koping, Trinh Vickie T., Chung William, Bowden Kyra, Troncoso Juan C., Blackshaw Seth, Hayes Lindsey R., Sun Shuying, Wong Philip C., Ling Jonathan P.ORCID
Abstract
Abstract
Background
Cytoplasmic inclusions and loss of nuclear TDP-43 are key pathological features found in several neurodegenerative disorders, suggesting both gain- and loss-of-function mechanisms of disease. To study gain-of-function, TDP-43 overexpression has been used to generate in vitro and in vivo model systems.
Methods
We analyzed RNA-seq datasets from mouse and human neurons overexpressing TDP-43 to explore species specific splicing patterns. We explored the dynamics between TDP-43 levels and exon repression in vitro. Furthermore we analyzed human brain samples and publicly available RNA datasets to explore the relationship between exon repression and disease.
Results
Our study shows that excessive levels of nuclear TDP-43 protein lead to constitutive exon skipping that is largely species-specific. Furthermore, while aberrant exon skipping is detected in some human brains, it is not correlated with disease, unlike the incorporation of cryptic exons that occurs after loss of TDP-43.
Conclusions
Our findings emphasize the need for caution in interpreting TDP-43 overexpression data and stress the importance of controlling for exon skipping when generating models of TDP-43 proteinopathy.
Publisher
Springer Science and Business Media LLC
Reference91 articles.
1. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VM-Y. Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130–3. 2. Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, Mann D, Tsuchiya K, Yoshida M, Hashizume Y, Oda T. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Bioph Res Co. 2006;351:602–11. 3. Hayes LR, Kalab P. Emerging therapies and novel targets for TDP-43 Proteinopathy in ALS/FTD. Neurotherapeutics. 2022;19:1061–84. 4. Meneses A, Koga S, O’Leary J, Dickson DW, Bu G, Zhao N. TDP-43 Pathology in Alzheimer’s Disease. Mol Neurodegener. 2021;16:84. 5. Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, Rademakers R, Alafuzoff I, Attems J, Brayne C, Coyle-Gilchrist ITS, Chui HC, Fardo DW, Flanagan ME, Halliday G, Hokkanen SRK, Hunter S, Jicha GA, Katsumata Y, Kawas CH, Keene CD, Kovacs GG, Kukull WA, Levey AI, Makkinejad N, Montine TJ, Murayama S, Murray ME, Nag S, Rissman RA, Seeley WW, Sperling RA, Schneider CLW. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142:1503-1527.
|
|